|会社名||Vertex Pharmaceuticals Inc. （バ―テックス・ファ―マシュ―ティカルズ）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 バーテックス・ファーマシューティカルズ（Vertex Pharmaceuticals Incorporated）は重篤な疾患の治療薬の発見・開発・生産・商品化に従事する会社である。同社は嚢胞性線維症（CF）の治療法の開発と商品化に注力し、他の適応症における研究開発プログラムの推進に取り組んでいる。同社の販売されている医薬品は、ORKAMBIおよびKALYDECOである。ORKAMBI（ivacaftorと組み合わせたlumacaftor）は、その嚢胞性線維症膜貫通コンダクタンス調節因子（CFTR）遺伝子にDelta-F508（F508del）突然変異を2コピー（同型接合）有する患者の治療薬として承認される。KALYDECO（ivacaftor）は、CFTR遺伝子にG551D突然変異または他の特定の突然変異を有するCF患者の治療のために承認されている。CF分野の開発プログラムには、Tezacaftor（VX-661）、VX-152、VX-440、VX-659、VX-445、VX-371などがあります。VX-152、VX-440、VX-659、VX-445はCFTR補正剤である。 バ―テックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。低分子薬品の発見、開発、製造、商業化に従事する。主要医薬品にはC型肝炎ウイルス治療薬「INCIVEK」と、嚢胞性線維症治療薬「KALYDECO」の2種類がある。その他、自己免疫疾患やインフルエンザ治療用の医薬品の開発にも従事。本社はボストン。 Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.|
|本社所在地||50 Northern Avenue Boston MA 02210 USA|
|代表者氏名||Jeffrey M. Leiden ジェフリー・M・ライデン|
|代表者役職名||Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Vertex Pharmaceuticals Incorporated revenues increased 11% to $1.39B. Net income applicable to common stockholders increased 57% to $417.5M. Revenues reflect Product revenues net increase of 40% to $1.39B. Net income benefited from Other income (expense) net increase from $3.1M (expense) to $150.7M (income) Restructuring expenses (income) decrease from $13.5M (expense) to $14K (income).|
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q1 2020 Earnings Call Transcript | AlphaStreet 2020/04/30 03:14:49 news.alphastreet.com
Final earnings conference call transcript of Vertex Pharmaceuticals Inc - VRTX stock
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates 2020/04/29 21:35:18 Zacks Investment Research
Vertex (VRTX) delivered earnings and revenue surprises of 39.89% and 19.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) reports Q1 2020 earnings results 2020/04/29 20:33:56 news.alphastreet.com
Vertex Pharmaceuticals (Nasdaq: VRTX) today reported first quarter financial results for the period ended March 31, 2020. On GAAP basis, first quarter EPS was $2.29 vs. $1.03 in the first quarter of 2019. Non-GAAP EPS was $2.56, compared to $1.14 in the first quarter of 2019. Total revenues increased 76% to $1.51 billion. You may […]
Vertex Pharmaceuticals (VRTX) reports Q1 2020 earnings results | AlphaStreet 2020/04/29 20:33:56 news.alphastreet.com
Vertex Pharmaceuticals (Nasdaq: VRTX) today reported first quarter financial results for the period ended March 31, 2020.
Vertex Reports First-Quarter 2020 Financial Results 2020/04/29 20:01:00 Business Wire
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2020 and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues. "The COVID-19 pandemic has presented unprecedented challenges to societies, communities and businesses around the world, and while these global challenges will continue for some time to come, I am very proud of how Vertex has re
This new treatment helps 90% of cystic fibrosis patients breathe better 2020/03/10 05:00:19 Fast Company
In October 2019, Vertex Pharmaceuticals received FDA approval for Trikafta, a cystic fibrosis treatment that could help 90% of patients with the deadly genetic disorder. Cystic fibrosis, which affects about 30,000 people in the U.S. (and has a life expectancy of 44 years for patients born today), is caused by mutations in the CFTR gene that lead to a defective protein being produced. That protein doesn’t allow chloride to flow in and out of cells normally (particularly those that line the lungs) and prevents water from hydrating the cellular surface, leading to a buildup of thick mucus and difficulty breathing. While other researchers looked to use gene therapy to address the disorder, Vertex’s team created a small-molecule drug that can tweak the faulty protein, allowing it to function more normally and drastically improving patient symptoms. “We were laughed at when we started,” says Vertex CEO Jeffrey Leiden. “No one thought that using small molecules would be enough to correct the underlying function of a giant protein.” In trials of more than 400 patients, Trikafta increased lung function by 13.8% versus a placebo, decreased hospitalizations, and boosted quality of life.
Vertex Pharmaceuticals : Buyers are coming back | MarketScreener 2020/03/05 13:21:18 MarketScreener
Vertex Pharmaceuticals shares have been in strong demand lately. The technical chart pattern looks positive which may give rise to new gains. | March 5, 2020
Vertex Pharmaceuticals : Cancels March 3 Presentation at Cowen Health Care Conference | MarketScreener 2020/03/02 21:24:05 MarketScreener
By Stephen Nakrosis Vertex Pharmaceuticals Inc. said Monday it was canceling a planned March 3 presentation and webcast at the Cowen Health Care Conference. Following implementation of a… | March 2, 2020
Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference 2020/03/02 20:44:00 Business Wire
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the cancellation of its planned March 3 presentation and webcast at the Cowen Healt
Why Is Vertex (VRTX) Down 2.7% Since Last Earnings Report? 2020/02/29 16:31:07 Zacks Investment Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This Biotech Stock Could Be Next In The $100B Market Cap Club, Citi Says 2020/02/14 19:49:11 Benzinga
Biotech stocks are risky investment bets, given they are at the mercy of several make-or-break catalysts. Citigroup highlighted three promising large-cap biotechs in a Friday note, naming one of these as its top pick. Citi's Ranking Criteria Mohit Bansal said it's using the following criteria for ranking its large-cap biotech names: Strength and valuation of base business Pipeline strength and riskiness Intellectual property and competition See Also: 3 Analysts Dissect Teva's Q4 Results Vertex Is A Winner Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) with the trifecta of … Full story available on Benzinga.com
What's in Store for Vertex in 2020 After a Remarkable 2019? 2020/02/14 09:11:00 Zacks Investment Research
In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data 2020/02/12 14:18:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: XLRN ) Agile Therapeutics Inc (NASDAQ: AGRX )( announced securing of loan facility) Allergan plc (NYSE: AGN ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE ) Cytokinetics, Inc. (NASDAQ: CYTK ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nevro Corp (NYSE: NVRO ) Novartis AG (NYSE: NVS )(announced priority review for its lung cancer drug) Pacira Biosciences Inc (NASDAQ: PCRX ) PAVmed Inc (NASDAQ: PAVM )(PAVmed's EsoGuard Esophageal DNA test was accorded Breakthrough Device designation) Penumbra Inc (NYSE: PEN ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Seattle Genetics, Inc. (NASDAQ: SGEN )(announced positive data readout for ADC in bladder cancer) Syneos Health Inc (NASDAQ: SYNH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 11) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) Brickell Biotech Inc (NASDAQ: BBI ) Endologix, Inc. (NASDAQ: ELGX ) Enzo Biochem, Inc. (NYSE: ENZ )( received New York State approval for its gynecological …
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology 2020/02/11 12:23:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc.
The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns 2020/02/07 12:32:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ALEC ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) Beam Therapeutics Inc (NASDAQ: BEAM ) (IPOed Thursday) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Fulgent Genetics Inc (NASDAQ: FLGT ) Insmed Incorporated (NASDAQ: INSM ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) Novartis AG (NYSE: NVS ) PPD Inc (NASDAQ: PPD ) (IPOed Thursday) Principia Biopharma Inc (NASDAQ: PRNB ) Profound Medical Corp (NASDAQ: PROF ) PTC Therapeutics, Inc (NASDAQ: PTCT ) ResMed Inc. (NYSE: RMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced FDA acceptance of BLA for DAXI to treat frown lines) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 バ―テックス・ファ―マシュ―ティカルズ VRTX Vertex Pharmaceuticals Incorporated）